# Lexicon Pharmaceuticals, Inc.

**LXRX**

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001062822

# D/E

**on the D/E boundary of 370 graded peers in healthcare**

rank 298 of 370; percentile 80.5; sampling error 2.5 points; lower is stronger

A B C D E

**D/E, the sloth**



| Scoreboard | |
|---|---|
| **Profitability** | D<br>percentile 71.5 |
| **Solvency** | C<br>percentile 52.4 |
| **Growth and financing** | C<br>percentile 56.1 |
| **Reliability** | 0.87 AUC<br>filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025 |
| **Peer failure rate** | 1.03% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $120M to $591M assets<br>total assets $185.0M |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | none triggered; fortress balance sheet |
| **Inputs computable** | 7 of 14 |
| **Graded from** | filings received through Mar 5, 2026<br>230 days before the rescan; latest periodic filing 10-Q received Aug 6, 2026 |
| **Last close** | $1.57<br>2026-10-20; market equity $700.8M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 5, 2026*

We are a biopharmaceutical company with a mission of pioneering medicines that transform patients' lives. We are devoting most of our resources to the research and development of our most advanced drug candidates and the commercialization of our approved drug, INPEFA® (sotagliflozin): ?We are developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for hypertrophic cardiomyopathy, or HCM, and are conducting the SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin in that indication. ?We are separately pursuing regulatory approval of ZYNQUISTA® (sotagliflozin) as a treatment for type 1 diabetes. The U.S.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 71.5** | | | | | | |
| Gross profitability | 26.8% | 32.3% | | 53.5 | 371 | 2025-12-31 |
| Return on invested capital | not computable | 9.3% | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | |
|---|---|---|---|---|---|---|
| *latest aligned inputs end 2016-12-31; latest annual assets end 2025-12-31* | | | | | | |
| Accruals ratio | 7.2% | (6.6%) | | 89.5 | 812 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | | |
| *annual revenue must exceed $100,000* | | | | | | |
| **Solvency, sleeve percentile 52.4** | | | | | | |
| Twelve-month failure probability | 0.05% | 0.06% | | 37.4 | 247 | 2026-06-30 |
| Altman Z double-prime | (33.00) | (0.30) | | 82.1 | 757 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | | |
| *EBITDA must exceed $100,000* | | | | | | |
| Interest coverage | not computable | (4.51x) | | | | |
| *latest aligned inputs end 2022-12-31; latest annual assets end 2025-12-31* | | | | | | |
| Current ratio | 4.88x | 2.96x | | 37.8 | 840 | 2025-12-31 |
| **Growth and financing, sleeve percentile 56.1** | | | | | | |
| Revenue growth, three-year compound | not computable | 10.1% | | | | |
| *current value must be positive and the base must exceed $100,000* | | | | | | |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | | |
| Reinvestment rate | not computable | 37.1% | | | | |
| *NOPAT must exceed $100,000* | | | | | | |
| Asset growth, three years | (1.6%) | 2.1% | | 54.7 | 705 | 2025-12-31 |
| Net share issuance, one year | 17.2% | 2.4% | | 57.4 | 633 | 2026-03-04 |

## Warnings

*1 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Fortress balance sheet | cash minus debt is 40,921,000 USD; Altman Z is not used |

## Among 370 peers

*healthcare; letters are fifths of this list*




*Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.*

| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 293 | Ironwood Pharmaceuticals Inc. (IRWD) | 79.1 | D/E | late filer, fortress balance sheet |
| 294 | X4 Pharmaceuticals, Inc. (XFOR) | 79.4 | D/E | dilution, fortress balance sheet |
| 295 | Champions Oncology, Inc. (CSBR) | 79.7 | D/E | |
| 296 | Lucid Diagnostics Inc. (LUCD) | 79.9 | D/E | dilution |
| 297 | Voyager Therapeutics, Inc. (VYGR) | 80.2 | D/E | short runway |
| 298 | Lexicon Pharmaceuticals, Inc. (LXRX) | 80.5 | D/E | fortress balance sheet |
| 299 | Merck & Co., Inc. (MRK) | 80.8 | D/E | |
| 300 | Personalis, Inc. (PSNL) | 81.0 | D/E | |
| 301 | Surgery Partners, Inc. (SGRY) | 81.3 | D/E | late filer |
| 302 | C4 Therapeutics, Inc. (CCCC) | 81.6 | D/E | dilution, fortress balance sheet |
| 303 | Hyperfine, Inc. (HYPR) | 81.8 | D/E | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

## What the price implies

*at the 2026-10-20 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | 66.7% | 8.0% | 82 |
| Distance from 52-week high | (40.2%) | (29.7%) | 36 |
| EBIT to enterprise value | (6.4%) | (1.5%) | 38 |
| Free cash flow yield | (9.7%) | (1.0%) | 32 |
| Book value to price | 0.25 | 0.28 | 46 |
| Sales to price | 0.07 | 0.30 | 20 |
| Composite equity issuance, five years | not computable | 20.5% | |
| Relative strength against the sector, log excess return | 0.30 | (0.13) | 82 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score 4 of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | pass |
| Operating cash flow exceeds net income | fail |
| Long-term leverage fell | pass |
| Current ratio improved | fail |
| No new shares issued | fail |
| Gross margin improved | pass |
| Asset turnover improved | pass |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $40.9M |
| Operating cash flow, four quarters | -$65.0M |
| Months of runway | 7.6 |
| Days since last periodic filing | 76 (10-Q received Aug 6, 2026) |
| Median daily dollar volume, 63 sessions | $5.1M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | revenue | us-gaap:Revenues | $49.8M | 2025-12-31 | 2026-03-05 | 10-K | 26-000050 |
| 2 | cost of revenue | us-gaap:CostOfGoodsAndServicesSold | $274,000 | 2025-12-31 | 2026-03-05 | 10-K | 26-000050 |
| 3 | assets | us-gaap:Assets | $185.0M | 2025-12-31 | 2026-03-05 | 10-K | 26-000050 |
| 4 | operating income | us-gaap:OperatingIncomeLoss | -$127.2M | 2016-12-31 | 2019-03-15 | 10-K | 19-000007 |
| 5 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$131.4M | 2016-12-31 | 2019-03-15 | 10-K | 19-000007 |
| 6 | income tax | us-gaap:IncomeTaxExpenseBenefit | $0 | 2016-12-31 | 2018-03-01 | 10-K | 18-000008 |
| 7 | total debt | us-gaap:LongTermDebt | $101.4M | 2016-12-31 | 2017-03-06 | 10-K | 17-000013 |
| 8 | book equity | us-gaap:StockholdersEquity | $167.5M | 2016-12-31 | 2020-03-12 | 10-K | 20-000015 |
| 9 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $46.6M | 2016-12-31 | 2020-03-12 | 10-K | 20-000015 |
| 10 | total debt | us-gaap:LongTermDebt | $105.8M | 2015-12-31 | 2016-03-11 | 10-K | 16-000051 |
| 11 | book equity | us-gaap:StockholdersEquity | $286.0M | 2015-12-31 | 2019-03-15 | 10-K | 19-000007 |
| 12 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $203.0M | 2015-12-31 | 2019-03-15 | 10-K | 19-000007 |
| 13 | net income | us-gaap:NetIncomeLoss | -$50.3M | 2025-12-31 | 2026-03-05 | 10-K | 26-000050 |
| 14 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$67.9M | 2025-12-31 | 2026-03-05 | 10-K | 26-000050 |
| 15 | assets | us-gaap:Assets | $298.4M | 2024-12-31 | 2026-03-05 | 10-K | 26-000050 |
| 16 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $6.0M | 2024-12-31 | 2025-03-07 | 10-K | 25-000013 |
| 17 | cost of revenue | us-gaap:CostOfGoodsAndServicesSold | $616,000 | 2024-12-31 | 2026-03-05 | 10-K | 26-000050 |
| 18 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $1.1M | 2023-12-31 | 2025-03-07 | 10-K | 25-000013 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| 19 | cost of revenue | us-gaap:CostOfGoodsAndServicesSold | $85,000 | 2023-12-31 | 2026-03-05 | 10-K | 26-000050 |
| 20 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $0 | 2022-12-31 | 2025-03-07 | 10-K | 25-000013 |
| 21 | cost of revenue | us-gaap:CostOfGoodsAndServicesSold | $0 | 2022-12-31 | 2025-03-07 | 10-K | 25-000013 |
| 22 | current assets | us-gaap:AssetsCurrent | $101.9M | 2025-12-31 | 2026-03-05 | 10-K | 26-000050 |
| 23 | current liabilities | us-gaap:LiabilitiesCurrent | $20.9M | 2025-12-31 | 2026-03-05 | 10-K | 26-000050 |
| 24 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$2.0B | 2025-12-31 | 2026-03-05 | 10-K | 26-000050 |
| 25 | operating income | us-gaap:OperatingIncomeLoss | -$48.9M | 2025-12-31 | 2026-03-05 | 10-K | 26-000050 |
| 26 | book equity | us-gaap:StockholdersEquity | $107.5M | 2025-12-31 | 2026-03-05 | 10-K | 26-000050 |
| 27 | liabilities | us-gaap:Liabilities | $77.4M | 2025-12-31 | 2026-03-05 | 10-K | 26-000050 |
| 28 | total debt | us-gaap:LongTermDebtAndCapitalLeaseObligations | $5.4M | 2022-12-31 | 2023-03-03 | 10-K | 23-000007 |
| 29 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $46.3M | 2022-12-31 | 2024-03-25 | 10-K | 24-000008 |
| 30 | operating income | us-gaap:OperatingIncomeLoss | -$100.8M | 2022-12-31 | 2025-03-07 | 10-K | 25-000013 |
| 31 | depreciation amortization | us-gaap:DepreciationDepletionAndAmortization | $427,000 | 2022-12-31 | 2025-03-07 | 10-K | 25-000013 |
| 32 | interest expense | us-gaap:InterestExpense | $2.8M | 2022-12-31 | 2023-03-03 | 10-K | 23-000007 |
| 33 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $0 | 2025-12-31 | 2026-03-05 | 10-K | 26-000050 |
| 34 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$178.8M | 2024-12-31 | 2026-03-05 | 10-K | 26-000050 |
| 35 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $1.0M | 2024-12-31 | 2026-03-05 | 10-K | 26-000050 |
| 36 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$161.9M | 2023-12-31 | 2026-03-05 | 10-K | 26-000050 |
| 37 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $470,000 | 2023-12-31 | 2026-03-05 | 10-K | 26-000050 |
| 38 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$88.9M | 2022-12-31 | 2025-03-07 | 10-K | 25-000013 |
| 39 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $1.3M | 2022-12-31 | 2025-03-07 | 10-K | 25-000013 |
| 40 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $231,000 | 2016-12-31 | 2019-03-15 | 10-K | 19-000007 |
| 41 | depreciation amortization | us-gaap:DepreciationDepletionAndAmortization | $2.1M | 2016-12-31 | 2019-03-15 | 10-K | 19-000007 |
| 42 | current assets | us-gaap:AssetsCurrent | $357.9M | 2016-12-31 | 2018-03-01 | 10-K | 18-000008 |
| 43 | current liabilities | us-gaap:LiabilitiesCurrent | $164.6M | 2016-12-31 | 2018-03-01 | 10-K | 18-000008 |
| 44 | current assets | us-gaap:AssetsCurrent | $532.4M | 2015-12-31 | 2017-03-06 | 10-K | 17-000013 |
| 45 | current liabilities | us-gaap:LiabilitiesCurrent | $123.0M | 2015-12-31 | 2017-03-06 | 10-K | 17-000013 |
| 46 | assets | us-gaap:Assets | $229.4M | 2023-12-31 | 2025-03-07 | 10-K | 25-000013 |
| 47 | assets | us-gaap:Assets | $194.3M | 2022-12-31 | 2024-03-25 | 10-K | 24-000008 |
| 48 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 423,680,611 | 2026-03-04 | 2026-03-05 | 10-K | 26-000050 |
| 49 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 361,492,295 | 2025-02-28 | 2025-03-07 | 10-K | 25-000013 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.